Hospital
DLP Person Memorial Hospital LLC
DLP Person Memorial Hospital LLC was paid $4.13M by Medicaid between Jan 2018 and Dec 2024, across 61 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoDLP PERSON MEMORIAL HOSPITAL LLC
ROXBORO, NC 27573
ROXBORO, NC 27573
33aNPI1881977593assigned 09/20/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.13M
24GClaims112,280
24DCodes billed61
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#64 of 92
Median peer was paid$11.47M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,532 | $602K | |
| 2019 | 20,617 | $485K | |
| 2020 | 11,306 | $316K | |
| 2021 | 13,697 | $519K | |
| 2022 | 14,567 | $683K | |
| 2023 | 15,489 | $745K | |
| 2024incomplete | 16,072 | $781K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 12,618 | 10,444 | $1.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 10,111 | 8,190 | $1.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 6,262 | 4,914 | $891K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.6% | 3,320 | 2,748 | $233K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 14,992 | 11,397 | $81K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.8% | 2,296 | 1,856 | $76K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 3,764 | 2,558 | $71K |
| 80053 | Comprehensive metabolic panel | 1.6% | 10,741 | 8,416 | $64K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 2,259 | 1,746 | $47K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.1% | 3,029 | 1,822 | $44K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,964 | 1,549 | $36K |
| 87400 | <1% | 2,716 | 2,321 | $33K |
49 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,016 | $28K |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,326 | $25K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 631 | $23K |
| G0378 | Hospital observation service, per hour | <1% | 108 | $21K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 614 | $17K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 589 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 703 | $11K |
| 84484 | <1% | 1,638 | $11K | |
| 83735 | <1% | 2,527 | $11K | |
| 83690 | <1% | 1,268 | $7K | |
| 81001 | <1% | 2,753 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 458 | $5K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 210 | $5K |
| 81025 | <1% | 719 | $5K | |
| 81003 | <1% | 2,424 | $4K | |
| 82553 | <1% | 673 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 110 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 641 | $3K |
| 87081 | <1% | 441 | $2K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 18 | $2K |
| 0012A | <1% | 37 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $2K |
| 82550 | <1% | 630 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 50 | $2K |
| 83880 | <1% | 134 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 582 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 14 | $1K |
| 85730 | <1% | 523 | $1K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 434 | $1K |
| 85610 | <1% | 710 | $1K | |
| 87430 | <1% | 99 | $1K | |
| 0011A | <1% | 36 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 44 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 373 | $917.15 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15 | $720.91 |
| 84100 | <1% | 252 | $660.01 | |
| 87807 | <1% | 45 | $562.91 | |
| 0064A | <1% | 13 | $355.15 | |
| J2704 | Injection, propofol, 10 mg | <1% | 46 | $287.76 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 46 | $154.08 |
| 83605 | <1% | 17 | $116.01 | |
| 80076 | <1% | 23 | $99.90 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 16 | $79.10 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 17 | $78.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 46 | $62.88 |
| 86140 | <1% | 19 | $51.41 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 34 | $36.89 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 22 | $20.31 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 52 | $12.35 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.